Respiratory physician Lutz Beckert considers chronic obstructive pulmonary disease management, including the prevention of COPD, the importance of smoking cessation and pulmonary rehabilitation, and the lifesaving potential of addressing treatable traits. He also discusses the logic of inhaler therapy, moving from single therapy to dual and triple therapy when indicated, as well as other aspects of management
Deciding when triple therapy will be beneficial for COPD
Deciding when triple therapy will be beneficial for COPD

We are on our summer break and the editorial office is closed until 13 January. In the meantime, please enjoy our Summer Hiatus series, in which our journalists curate an eclectic mix from our news and clinical archives throughout the year, The Conversation and other publications we share content with. Please note the comment function has been turned off while we are away. Happy reading!
This article was first published online on 11 September 2024.
Pharmacist prescriber Linda Bryant delves into the details of prescribing inhaled corticosteroids for patients with chronic obstructive pulmonary disease
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.
1. Hancox RJ, Jones S, Baggott C, et al. New Zealand COPD Guidelines: Quick Reference Guide. N Z Med J 2021;134(1530):76–110. https://www.asthmafoundation.org.nz/health-professionals/management-guidelines/nz-copd-guidelines
2. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2024. https://goldcopd.org/2024-gold-report/
3. Hoogendoorn M, Hoogenveen RT, Rutten-van Mölken MP, et al. Case fatality of COPD exacerbations: a meta-analysis and statistical modelling approach. Eur Respir J 2011;37(3):508–15.
4. Ho TW, Tsai YJ, Ruan SY, et al. In-hospital and one-year mortality and their predictors in patients hospitalized for first-ever chronic obstructive pulmonary disease exacerbations: a nationwide population-based study. PLoS One 2014;9(12):e114866.
5. Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005;60(11):925–31.
6. Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177(1):19–26.
7. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356(8):775–89.
8. Cates C. Inhaled corticosteroids in COPD: quantifying risks and benefits. Thorax 2013;68(6):499–500.
9. Mathioudakis AG, Bate S, Sivapalan P, et al Rethinking blood eosinophils for assessing ICS response in COPD: A post hoc analysis from FLAME. Chest 2024; 9 July online.